| Literature DB >> 32620160 |
Sara Hanaei1,2,3, Sina Abdollahzade4, Maryam Sadr1, Mohammad Hossein Mirbolouk5, Ehsan Fattahi5, Alireza Khoshnevisan5, Nima Rezaei6,7,8.
Abstract
BACKGROUND: Intervertebral disc degeneration (IVDD) is an age-related degenerative disease, presenting with low back pain or radicular pain. The inflammatory changes would occur in discs in the process of IVDD. Therefore, the inflammatory and anti-inflammatory cytokines, as well as their respective genes, have been proposed to play roles in pathophysiology of disease. This study has been conducted to elucidate the role of IL-2, IL-12, and IFN-γ single nucleotide polymorphisms (SNP) in this disease.Entities:
Keywords: Cytokine; Immunogenetics; Interferon γ; Interleukin 12; Interleukin 2; Intervertebral disc degeneration; Single nucleotide polymorphism
Year: 2020 PMID: 32620160 PMCID: PMC7333426 DOI: 10.1186/s12881-020-01081-3
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
The frequencies of cytokine alleles and genotypes in IVDD patients and healthy controls
| Cytokine | Position | Alleles/ Genotypes | IVDD | Control ( | OR | 95% CI | |
|---|---|---|---|---|---|---|---|
| IL-12 ( | -1188 (rs3212227) | A | 103 (72.5) | 204(72.9) | 1.00 | 0.98 | 0.63–1.55 |
| C | 39 (27.5) | 76(27.1) | 1.00 | 1.02 | 0.65–1.58 | ||
| AA | 40 (56.3) | 72(51.4) | 0.56 | 1.22 | 0.69–2.16 | ||
| CA | 23 (32.4) | 60(42.9) | 0.18 | 0.64 | 0.35–1.16 | ||
| CC | 8 (11.3) | 8(5.7) | 0.17 | 2.09 | 0.75–5.84 | ||
| IFN-γ ( | + 874 (rs2430561) | A | 85 (57.4) | 140(50.7) | 0.22 | 1.31 | 088–1.96 |
| T | 63 (42.6) | 136(49.3) | 0.22 | 0.88 | 0.51–1.31 | ||
| AA | 26 (35.1) | 43(31.2) | 0.65 | 1.19 | 0.66–2.18 | ||
| AT | 33 (44.6) | 54(39.1) | 0.47 | 1.25 | 0.71–2.19 | ||
| TT | 15 (20.3) | 41(29.7) | 0.15 | 0.60 | 0.31–1.18 | ||
| IL-2 ( | -330 (rs2069762) | G | 68 (46.0) | 110(39.6) | 0.21 | 1.31 | 0.88–1.97 |
| T | 80 (54.0) | 168(60.4) | 0.21 | 0.76 | 0.50–1.13 | ||
| GG | 4 (5.4) | 8(5.8) | 1.00 | 0.94 | 0.27–3.22 | ||
| IL-2 ( | + 166 (rs2069763) | G | 113 (76.4) | 219(78.8) | 0.62 | 0.87 | 0.54–1.40 |
| T | 35 (23.6) | 59(21.2) | 0.62 | 1.15 | 0.71–1.85 | ||
| GG | 40 (54.1) | 82(59) | 0.56 | 0.82 | 0.46–1.44 | ||
| GT | 33 (44.6) | 55(39.6) | 0.56 | 1.23 | 0.69–2.17 | ||
| TT | 1 (1.4) | 2(1.4) | 1.00 | 0.94 | 0.08–10.52 |
The frequencies of IL-2 haplotypes in IVDD patients and healthy controls
| Cytokine | Haplotype* | IVDD | Control ( | OR | 95% CI | |
|---|---|---|---|---|---|---|
| IL-2 | GG | 48 (32.2) | 107(38.8) | 0.20 | 0.75 | 0.49–1.14 |
| TG | 65 (43.6) | 112(40.6) | 0.60 | 1.13 | 0.76–1.69 | |
| TT | 56(20.3) | |||||
| GT | 1(0.3) |
*Reference: The IL2 haplotype was comprised of -330 T/G SNP (rs2069762), and + 166G/T SNP (rs2069763)
Association between cytokine genotypes and 2 months or 6 months postop OSW changes in IVDD patients
| Cytokine | Position | Genotype | 2 months postop | 6 months postop | ||
|---|---|---|---|---|---|---|
| MD ± SD (MD) | MD ± SD (MD) | |||||
| IL-12 | -1188 | AA | −18.75 ± 5.69 | 0.19 | −24.54 ± 5.60 | 0.07 |
| CA | −21.36 ± 6.01 | −27.59 ± 3.69 | ||||
| CC | −21.50 ± 5.08 | −26.50 ± 5.16 | ||||
| IFN-γ | + 874 | AA | −20.08 ± 5.44 | 0.99 | −25.82 ± 4.54 | 0.98 |
| AT | −20.11 ± 5.92 | − 25.92 ± 5.18 | ||||
| TT | −20.35 ± 6.12 | − 25.57 ± 6.33 | ||||
| IL-2 | −330 | GG | −27.50 ± 0.70 | 0.12 | −28.00 ± 2.82 | 0.82 |
| TG | −19.54 ± 5.90 | −25.80 ± 5.27 | ||||
| TT | −21.37 ± 4.03 | −25.50 ± 4.75 | ||||
| IL-2 | + 166 | GG | −20.66 ± 5.38 | 0.33 | −26.21 ± 4.27 | 0.27 |
| GT | −19.12 ± 6.14 | −25.19 ± 5.85 | ||||
| TT | −26.00 | −33.00 | ||||
Association between cytokine genotypes and 2 months or 6 months postop VAS changes in IVDD patients
| Cytokine | Position | Genotype | 2 months postop | 6 months postop | ||
|---|---|---|---|---|---|---|
| MD ± SD (MD) | MD ± SD (MD) | |||||
| IL-12 | −1188 | AA | −4.37 ± 1.42 | 0.52 | −5.62 ± 1.29 | 0.49 |
| CA | −4.77 ± 1.10 | − 5.90 ± 1.06 | ||||
| CC | −4.50 ± 0.83 | −6.16 ± 1.47 | ||||
| IFN-γ | + 874 | AA | −4.65 ± 1.19 | 0.49 | −5.86 ± 1.09 | 0.92 |
| AT | −4.37 ± 1.49 | −5.74 ± 1.48 | ||||
| TT | −4.85 ± 0.94 | −5.85 ± 0.94 | ||||
| IL-2 | −330 | GG | −6.00 ± 0 | 0.22 | − 6.00 ± 0 | 0.88 |
| TG | −4.56 ± 1.31 | −5.83 ± 1.21 | ||||
| TT | −4.25 ± 0.88 | −5.62 ± 1.50 | ||||
| IL-2 | + 166 | GG | −4.57 ± 1.27 | 0.90 | −5.84 ± 1.12 | 0.18 |
| GT | −4.58 ± 1.31 | −5.70 ± 1.29 | ||||
| TT | −4.00 | −8.00 | ||||
Association between cytokine allele frequencies and 2 months or 6 months postop OSW changes in IVDD patients
| Cytokine | Position | Allele | 2 months postop | 6 months postop | ||
|---|---|---|---|---|---|---|
| MD ± SD (MD) | MD ± SD (MD) | |||||
| IL-12 | −1188 | A | −19.35 ± 5.81 | 0.07 | −25.23 ± 5.33 | |
| C | −21.41 ± 5.55 | −27.20 ± 4.13 | ||||
| IFN-γ | + 874 | A | −20.09 ± 5.54 | 0.89 | − 25.86 ± 4.72 | 0.89 |
| T | −20.23 ± 5.91 | −25.74 ± 5.68 | ||||
| IL-2 | −330 | G | −20.08 ± 6.04 | 0.90 | −25.94 ± 5.14 | 0.81 |
| T | −19.95 ± 5.54 | −25.73 ± 5.09 | ||||
| IL-2 | + 166 | G | −20.17 ± 5.62 | 0.58 | −25.88 ± 4.80 | 0.83 |
| T | −19.54 ± 6.17 | −25.66 ± 5.97 | ||||
Association between cytokine allele frequencies and 2 months or 6 months postop VAS changes in IVDD patients
| Cytokine | Position | Allele | 2 months postop | 6 months postop | ||
|---|---|---|---|---|---|---|
| MD ± SD (MD) | MD ± SD (MD) | |||||
| IL-12 | −1188 | A | −4.46 ± 1.35 | 0.41 | −5.68 ± 1.24 | 0.20 |
| C | −4.67 ± 1.00 | −6.00 ± 1.18 | ||||
| IFN-γ | + 874 | A | −4.54 ± 1.30 | 0.75 | −5.82 ± 1.23 | 0.92 |
| T | −4.61 ± 1.25 | −5.80 ± 1.22 | ||||
| IL-2 | −330 | G | −4.66 ± 1.32 | 0.45 | −5.84 ± 1.17 | 0.78 |
| T | −4.49 ± 1.22 | −5.78 ± 1.26 | ||||
| IL-2 | + 166 | G | −4.57 ± 1.27 | 0.90 | −5.80 ± 1.16 | 0.85 |
| T | −4.54 ± 1.27 | −5.84 ± 1.37 | ||||